gp160 MN/LAI-2

BIOLOGICAL4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Walter Reed Army Institute of Research (WRAIR)

Conditions

HIV InfectionsHIV Seronegativity

Phase 1

A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years

CompletedNCT00006509

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2007-06-30Target: 12Updated: 2015-03-09

Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults

CompletedNCT00000904

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 1999-08-31Target: 100Updated: 2021-11-04

A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection

CompletedNCT00004579

Walter Reed Army Institute of Research (WRAIR)HIV Infections, HIV Seronegativity

Start: 1998-04-30Updated: 2005-06-24

Unknown Phase

The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys

CompletedNCT00031109

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2005-05-31Target: 10Updated: 2021-10-15

Related Papers

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene

The Journal of Infectious Diseases2016-02-1119 citations